{"id":653184,"date":"2020-04-27T08:51:49","date_gmt":"2020-04-27T12:51:49","guid":{"rendered":"https:\/\/spaceweekly.com\/?p=653184"},"modified":"2020-04-27T08:51:49","modified_gmt":"2020-04-27T12:51:49","slug":"compugen-sees-encouraging-signals-from-early-stage-cancer-trial","status":"publish","type":"post","link":"https:\/\/spaceweekly.com\/?p=653184","title":{"rendered":"Compugen sees &#039;encouraging signals&#039; from early-stage cancer trial"},"content":{"rendered":"<p>Israeli cancer immunotherapy firm Compugen said on Monday it had positive initial results from an ongoing early-stage study of its COM701 therapy in patients with advanced solid tumours who have exhausted all standard treatments.<\/p>\n<div class=\"feedflare\">\n<a href=\"http:\/\/feeds.reuters.com\/~ff\/reuters\/scienceNews?a=W4mzlVv0xag:fz_4hlD-5lY:yIl2AUoC8zA\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"\" border=\"0\" \/><\/a> <a href=\"http:\/\/feeds.reuters.com\/~ff\/reuters\/scienceNews?a=W4mzlVv0xag:fz_4hlD-5lY:F7zBnMyn0Lo\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"\" border=\"0\" \/><\/a> <a href=\"http:\/\/feeds.reuters.com\/~ff\/reuters\/scienceNews?a=W4mzlVv0xag:fz_4hlD-5lY:V_sGLiPBpWU\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"\" border=\"0\" \/><\/a>\n<\/div>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"\" height=\"1\" width=\"1\" alt=\"\" \/>&#013;<br \/>\n&#013;<br \/>\n&#013;<br \/>\n Click here for original story, <a href=\"http:\/\/feeds.reuters.com\/~r\/reuters\/scienceNews\/~3\/W4mzlVv0xag\/compugen-sees-encouraging-signals-from-early-stage-cancer-trial-idUSKCN2291OX\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Compugen sees &#8216;encouraging signals&#8217; from early-stage cancer trial<\/a>&#013;<br \/>\n&#013;<br \/>\n&#013;<br \/>\nSource: Reuters Science News&#013;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Israeli cancer immunotherapy firm Compugen said on Monday it had positive initial results from an ongoing early-stage study of its COM701 therapy in patients with advanced solid tumours who have&hellip; <\/p>\n","protected":false},"author":1,"featured_media":615444,"comment_status":"false","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["post-653184","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-genaero"],"_links":{"self":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts\/653184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=653184"}],"version-history":[{"count":0,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts\/653184\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/media\/615444"}],"wp:attachment":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=653184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=653184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=653184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}